Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019

December 2019 | 66 pages | ID: L30FC27C0750EN
Global Markets Direct

Abstracts

Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019'; Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Leucine-rich repeat kinase 2 (LRRK2) is an enzyme encoded by the PARK8 gene. It plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner together with RAB29. It regulates neuronal process morphology in the intact central nervous system.

The report 'Leucine Rich Repeat SerineThreonine Protein Kinase 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 9 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Oncology and Ophthalmology which include indications Parkinson's Disease, Neurodegenerative Diseases, Alzheimer's Disease, Ocular Hypertension, Open-Angle Glaucoma, Pulmonary Hypertension and Solid Tumor.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
• The report reviews Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Overview
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
GlaxoSmithKline Plc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi
Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Drug Profiles
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARN-1104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNL-151 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Pipeline by Cerevel Therapeutics LLC, H2 2019
Pipeline by D. Western Therapeutics Institute Inc, H2 2019
Pipeline by Denali Therapeutics Inc, H2 2019
Pipeline by E-scape Bio Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by H. Lundbeck AS, H2 2019
Pipeline by Imago Pharmaceuticals Inc, H2 2019
Pipeline by Ionis Pharmaceuticals Inc, H2 2019
Pipeline by Lead Discovery Center GmbH, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NeuBase Therapeutics Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Pipeline by Origenis GmbH, H2 2019
Pipeline by Voronoi, H2 2019
Dormant Projects, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Arrien Pharmaceuticals LLC
Cerevel Therapeutics LLC
D. Western Therapeutics Institute Inc
Denali Therapeutics Inc
E-scape Bio Inc
GlaxoSmithKline Plc
H. Lundbeck AS
Imago Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
Lead Discovery Center GmbH
Merck & Co Inc
NeuBase Therapeutics Inc
Oncodesign SA
Origenis GmbH
Voronoi